Psoriasis Drug Guselkumab Improved Psoriatic Arthritis Symptoms
Guselkumab, a biologic drug approved to treat patients with moderate or severe psoriasis, significantly and safely improved psoriatic arthritis, a phase 3 trial in The Lancet concluded. Guselkumab is a...
View ArticleSkin Psoriasis, Somatic Comorbidity, and Psychiatric Illness in a Nationwide...
This matched case-control study investigates the independent association of skin psoriasis and somatic comorbidity with the development of psychiatric illness and assesses whether skin psoriasis and...
View ArticleMental Health of Patients With Psoriasis and Their Satisfaction With Physicians
This survey study uses data from the Medical Expenditure Panel Survey to examine the association between mental health comorbidities in patients with psoriasis and their satisfaction with physicians.
View ArticleMelanoma Risk in Patients Treated With Biologic Therapy for Common...
This systematic review and meta-analysis examines whether biologic treatment of inflammatory bowel disease, rheumatoid arthritis, or psoriasis is associated with increased risk of melanoma compared...
View ArticleRisk of Neuroinflammatory Adverse Events With TNF Inhibitor
Tumor necrosis factor (TNF) inhibitors have been widely used for the treatment of autoimmune disease since 1998, when the first biological agents were licensed in the United States. Several biosimilar...
View ArticleAssociation Between TNF Inhibitor Exposure and Inflammatory CNS Events
This case-control study examines the inflammatory CNS event outcome among patients with an autoimmune disease who were treated with tumor necrosis factor inhibitors.
View ArticleTrends in List and Net Price of Psoriasis Therapies From US Pharmaceutical...
This economic evaluation reviews the trends in list and net price data from SSR Health for the 2007 to 2019 period of self-administered systemic psoriasis medications manufactured in the United States.
View ArticleEffectiveness and Safety of Systemic Therapy for Psoriasis in Older Adults
This systematic review evaluates the effectiveness and safety of systemic antipsoriatic therapies in patients 65 years or older.
View ArticleAssociation of the Psoriatic Microenvironment With Treatment Response
This study examines a novel decision analytical model designed to measure mRNA gene expression changes to define the psoriatic microenvironment and assess medication response before a change in the...
View ArticleEarly Severe Cardiovascular Events and the Initiation of Ustekinumab
This case-time-control analysis uses data from the French national health insurance database to assess whether the initiation of ustekinumab treatment is associated with triggering severe...
View ArticleAssociation of Clinical and Demographic Factors With the Severity of...
This cross-sectional study examines factors that may contribute to the severity of symptoms in patients with palmoplantar pustulosis.
View ArticleTofacitinib for Nail Lesions and Palmoplantar Pustulosis in Synovitis, Acne,...
This case series study examines the use of tofacitinib for treating nail involvement in Chinese women with synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome.
View ArticleSecukinumab and Tuberculosis Reactivation in Patients With Psoriasis,...
This qualitative study evaluates the safety of newer biological agents for the treatment of tuberculosis infection and activation in patients with psoriasis, psoriatic arthritis, and ankylosing...
View ArticleTrends in List and Net Price of Psoriasis Therapies From US Pharmaceutical...
This economic evaluation reviews the trends in list and net price data from SSR Health for the 2007 to 2019 period of self-administered systemic psoriasis medications manufactured in the United States.
View ArticleAssociation of the Psoriatic Microenvironment With Treatment Response
This study examines a novel decision analytical model designed to measure mRNA gene expression changes to define the psoriatic microenvironment and assess medication response before a change in the...
View ArticleEffect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe...
This secondary analysis of 2 randomized clinical trials compares patient-reported outcomes of treatment with risankizumab vs ustekinumab and placebo in psoriasis symptoms, health-related quality of...
View ArticleEffectiveness and Safety of Systemic Therapy for Psoriasis in Older Adults
This systematic review evaluates the effectiveness and safety of systemic antipsoriatic therapies in patients 65 years or older.
View ArticleEarly Severe Cardiovascular Events and the Initiation of Ustekinumab
This case-time-control analysis uses data from the French national health insurance database to assess whether the initiation of ustekinumab treatment is associated with triggering severe...
View ArticleAssociation of Clinical and Demographic Factors With the Severity of...
This cross-sectional study examines factors that may contribute to the severity of symptoms in patients with palmoplantar pustulosis.
View ArticlePsoriasis Flares Following Systemic Glucocorticoid Exposure in Patients With...
This cohort study examines the rates and types of psoriasis flares during or within 3 months after concluding systemic corticosteroid administration in adult patients with a known history of psoriasis.
View Article